ADVERTISEMENT FEATURE


“One consistent implementation lesson is that enthusiasm is rarely the limiting factor”


Adoption tends to accelerate when system-wide operational and clinical leaders can point to real-world evidence from comparable services showing pathway impact on decisions, flow, and escalation. I would debate that commissioners and governing bodies prefer the most cost-effective community models. Subsequently, this creates overly complex programme expectations, often spanning outcomes, flow, access, and system efficiency, which can dilute implementation and focus. NHS England urgent community care guidance is explicit that safe out-of-hospital care depends on effective governance and appropriate clinical decision-making. Ownership ambiguity is therefore not a minor operational issue; it is a governance risk. 1. Ownership is the first challenge. Who owns quality and training? Who owns the pathway decisions? Who owns the operational response when demand surges? Without clear ownership, practice becomes variable, and confidence in the deployment erodes.


2. Workforce challenges. Staffing is continually under pressure in winter. Skill mix changes. Inexperienced staff rotate in. Sustaining competence and consistent actions requires a clear training model, time to develop skills, defining roles or scope of practice, and escalation rules that work in hours, as well as evenings and weekends.


3. Estates and infection control constraints. Safe sampling, patient separation, and clean workflows are easier to describe than to deliver in crowded environments. UKHSA emphasises proportionate, risk based, time limited interventions to protect wellbeing while managing outbreaks. The principle applies in clinical estates too. We need practical workflows that reduce mixing without creating bottlenecks.


4. Digital integration and architecture challenges. A respiratory result that does not reliably appear in the patient clinical record becomes a latent patient safety and/or governance risk because it cannot be easily audited or captured automatically, and it cannot support continuity when patients re-present to healthcare settings. This is not optional. It is part of safe pathway design.


5. Timing and motivation is a recurrent challenge. If winter pathway design begins when the surge has already arrived, the system will default to the safest looking option, which often becomes conveyance and admission.


WHAT TO MEASURE IF WE WANT TO LEARN AND SCALE u If a winter respiratory pathway is working, the measures should reflect both patient experience and system performance.


u Time to decision: This is the mechanism. If time to decision does not improve, the pathway is not reducing uncertainty.


u Escalation and conveyance rate from community UTC for influenza like illness presentations: This tests whether uncertainty is being resolved earlier.


u Admission rates and reasons for escalation: This tests whether escalation clarity and early disease recognition pathways are improving.


u Record completeness and result visibility: This tests governance and safety.


These measures align with the intent of urgent care, ARI hub models and urgent community care decision frameworks, which depend on reliable decision-making and safe governance across interfaces.


PRACTICAL TAKEAWAYS


FOR WINTER PLANNING u Start pathway design while the winter headache remains – in early spring and finalise at the end of summer, not during the upslope of a surge. Design point-of- care testing around decisions and place it where it changes disposition. Agree ownership across urgent care, pathology governance, IPC, and virology for thresholds and escalation rules. Ensure results land reliably in the clinical record so decisions are auditable, and continuity is protected.


SUMMARY


Winter resilience is no longer defined by capacity alone but by the speed and reliability of clinical decision-making across system interfaces. Embedding rapid diagnostics as decision infrastructure enables earlier risk stratification, reduces avoidable escalation, and strengthens governance across urgent and acute pathways. Without this shift, services will continue to default to risk-based escalation under uncertainty, perpetuating avoidable pressure on emergency care.


References u NHS England, 2023. https://www.england.nhs.uk/long-read/integrating-in-


vitro-point-of-care-diagnostics-guidance-for-urgent-community-response-and- virtual-ward-services/ (Accessed 8th May 2026).


u NHS England, 2024. https://www.england.nhs.uk/long-read/combined-adult- and-paediatric-acute-respiratory-infection-ari-hubs/ (Accessed 8th May 2026).


u NHS England, 2026. https://www.england.nhs.uk/publication/urgent- community-care-clinical-decision-making-framework/ (Accessed 8th May 2026).


u UK Health Security Agency, 2024. https://www.gov.uk/government/ publications/acute-respiratory-disease-managing-outbreaks-in-care-homes (Accessed 8th May 2026).


u UK Health Security Agency, 2024. https://www.gov.uk/government/ publications/acute-respiratory-disease-managing-outbreaks-in-care-homes/ management-of-acute-respiratory-infection-outbreaks-in-care-homes- guidance (Accessed 8th May 2026).


u UK Health Security Agency, 2026. https://www.gov.uk/government/ publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents/ guidance-on-use-of-antiviral-agents-for-the-treatment-and-prophylaxis-of- seasonal-influenza (Accessed 8th May 2026).


u UK Health Security Agency and Department of Health and Social Care, 2025. https://www.cas.mhra.gov.uk (Accessed 8th May 2026).


RDx-26001558 | 05/26


This is a sponsored advertorial placed by Abbott Rapid Diagnostics, Infectious Diseases.


June 2026 WWW.PATHOLOGYINPRACTICE.COM 29


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56